Translations:Insulin glargine/9/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
14,944 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 11:00, 20 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Insulin glargine)
<!-- Society and culture -->
Insulin glargine was approved for medical use in the United States in 2000. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]]. In 2021, it was the 29th most commonly prescribed medication in the United States with more than 19{{nbsp}}million prescriptions. In July 2021, the US [[Food and Drug Administration]] (FDA) approved an interchangeable [[biosimilar]] insulin product called Semglee (insulin glargine-yfgn) for the treatment of diabetes.

Insulin glargine was approved for medical use in the United States in 2000. It is on the World Health Organization's List of Essential Medicines. In 2021, it was the 29th most commonly prescribed medication in the United States with more than 19 million prescriptions. In July 2021, the US Food and Drug Administration (FDA) approved an interchangeable biosimilar insulin product called Semglee (insulin glargine-yfgn) for the treatment of diabetes.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_glargine/9/en&oldid=130429"